现场 扬子晚报网2月3日讯(通讯员王誉橙黄为民记者万凌云姜天圣)1月30日至2月1日，经过由中国合格评定国家认可委员会(CNAS)委派的五位国家级权威专家 连续三天的严格评审，扬中市人医检验科成功通过ISO15189医学实验室认可的现场评审。这标志着扬中市人医检验科在质量与能力建设上取得重大阶段 性成果，向获得全球公认的医学实验室"金标准"认可迈出了最关键的一步。 现场 现场 据悉，本次现场评审专家组阵容强大，由山东大学齐鲁第二医院公衍文主任担任组长，成员涵盖中国人民解放军总医院张有江主任、四川省人民医院传良 敏主任、东部战区总医院时永辉主任和南京市第一医院何帮顺主任，五位专家均为医学检验领域的权威人士，确保了评审工作的专业性、严谨性和公正 性。 此次现场评审，被业内称为对医学实验室的"终极体检"，评审过程全面、系统且严苛。三天时间里，专家组严格依照ISO15189国际标准，通过查阅海量管 理文件、追踪检验原始记录、现场考核实操能力、深度访谈实验室工作人员、走访临床相关科室等多种方式，对扬中市人医检验科的管理体系运行、技术 能力水平进行了全方位、无死角的核查。评审范围覆盖从患者样本接收到检验报告发出的全过程， ...

Core Viewpoint - GIC Private Limited has increased its stake in Adicon Holdings (09860), acquiring 891,500 shares at HKD 5 per share, totaling HKD 4.4575 million, bringing its total holdings to 36.8375 million shares, representing 5.07% ownership, triggering a mandatory disclosure [1] Group 1: Company Developments - Adicon's strategic focus on AI in medical testing has garnered significant market attention, transitioning from traditional models to intelligent and ecological approaches [1] - The company signed a cooperation agreement with Huawei Cloud in December, marking the beginning of a new chapter in smart healthcare powered by AI technology [1] - Adicon announced plans to acquire Crown Bioscience for up to USD 204 million by November 2025, which will enhance its capabilities in drug development and diagnostics [1] Group 2: Market Reactions - Jefferies has issued a "Buy" rating for Adicon Holdings with a target price of HKD 12.60, citing the company's strategic moves in AI medical testing and the acquisition of Crown Bioscience as key factors [2] - Analysts suggest that GIC's stake increase may create a demonstration effect, promoting Adicon's ecological expansion in the AI medical sector and solidifying its position as a leading quality asset in the industry [2]

Group 1 - GIC Private Limited increased its stake in Adicon Holdings (09860) by purchasing 891,500 shares at HKD 5 per share, totaling HKD 4.4575 million, bringing its total holdings to 36.8375 million shares, representing 5.07% of the company, officially triggering the takeover threshold [1] - Adicon's strategic focus on AI in medical testing has garnered significant market attention, as the company transitions its medical testing services from traditional models to intelligent and ecological approaches [1] - In December 2022, Adicon signed a cooperation agreement with Huawei Cloud to initiate a new chapter in smart healthcare powered by AI technology, showcasing its technological iteration path and forward-looking layout in AI medical innovation applications [1] Group 2 - Adicon announced plans to acquire Crown Bioscience for up to USD 204 million, which is expected to significantly enhance the company's comprehensive strength in the drug development and diagnostic value chain [1] - Jefferies Financial has issued a "Buy" rating for Adicon Holdings (09860) with a target price of HKD 12.60, citing the company's strategic layout in AI medical testing and the acquisition of Crown Bioscience as major initiatives to strengthen its position [2] - Analysts suggest that GIC's stake increase may create a demonstration effect, promoting Adicon's ecological expansion in the AI medical field and further solidifying its market position as a leading quality asset in the industry [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、本期业绩预告的具体适用情形：净利润为负值。 2、广州金域医学检验集团股份有限公司（以下简称"公司"）预计2025年年度实现归属于上市公司股东 的净利润为-13,000万元到-19,000万元，与上年同期相比，将同比减亏19,124.11万元到25,124.11万元。 3、公司预计2025年年度实现归属于上市公司股东的扣除非经常性损益的净利润为-12,000万元到-18,000 万元。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1、经财务部门初步测算，预计2025年年度实现归属于上市公司股东的净利润为-13,000万元到-19,000万 元，与上年同期相比，将同比减亏19,124.11万元到25,124.11万元。 2、公司预计2025年年度实现归属于上市公司股东的扣除非经常性损益的净利润为-12,000万元到-18,000 万元。 （三）本次所预计的业绩未经审计机构审计。 二、上年同期业绩情况 ...

齐鲁晚报.齐鲁壹点陈甜田通讯员孙善月徐大伟隋奎印 滨州市人民医院检验科顺利通过中国合格评定国家认可委员会(CNAS)ISO15189医学实验室认可初次现场评审，成为滨州市首家通过现场评审的实验室。 这标志着滨州市人民医院检验工作正式接轨国际"金标准"，检验质量与服务水平再上新台阶！ ISO15189，全称为《医学实验室—质量和能力的要求》，是由国际标准化组织发布的国际标准。该标准规定了医学实验室质量和能力的专用要求，旨在 推动实验室建立质量管理体系，并确保其具备持续提供技术上有效、管理上规范检验结果的能力，同时满足患者和医疗服务用户的临床需求。 获得ISO15189认可，意味着该医学实验室的管理体系和技术能力，符合这一国际金标准的要求，其出具的检验报告在全球范围内具有更高的可信度、有 效性和互认性。 此次评审由国内检验界知名专家组成评审团，中国人民解放军总医院第五医学中心李伯安担任评审组长，山东大学齐鲁第二医院检验医学中心公衍文、中 南大学湘雅医院钟白云、山东第一医科大学附属省立医院刘相东、广西中医药大学第一附属医院李明芬担任评审组成员。 评审组组长李伯安主持会议。 杨玉龙表示，滨州市人民医院检验科作为滨州市 ...

Group 1 - The company is a leading provider of integrated molecular diagnostic products and services in China [1] - The strategic plan focuses on the collaborative development of three business segments: molecular diagnostic products, medical testing services, and healthcare services [1] - The company has not yet ventured into the brain-computer interface business [1]

Core Viewpoint - The company, Guangzhou Kingmed Diagnostics Group Co., Ltd., anticipates a net loss for the fiscal year 2025, primarily due to extended collection periods for accounts receivable leading to significant credit impairment losses [1]. Financial Performance - The company expects the net profit attributable to shareholders for 2025 to be negative, indicating an operational loss for the year [1]. - The final financial data will be disclosed in the official 2025 annual report, which will provide the confirmed figures [1]. Compliance and Disclosure - The company commits to adhering to the Shanghai Stock Exchange listing rules and will expedite its financial accounting processes to release the 2025 annual performance forecast promptly [1]. - Designated media for information disclosure includes China Securities Journal, Shanghai Securities Journal, Securities Times, Securities Daily, and the Shanghai Stock Exchange website [1].

Group 1 - The core point of the article is that Capbio (SZ 300639) announced the pledge and extension of shares by its major shareholder, Yunnan Zhonghezhi, which may impact the company's stock performance and liquidity [1] - Yunnan Zhonghezhi has pledged a total of 10.45 million shares to Hongta Securities for release and has extended the pledge of 19 million shares, with a total of 25.93 million shares pledged, accounting for 4.13% of the company's total share capital [1] - As of the announcement date, Capbio's market capitalization is 3.8 billion yuan [1] Group 2 - For the first half of 2025, Capbio's revenue composition is as follows: molecular diagnostic products account for 67.65%, medical testing services for 29.07%, and medical service income for 3.27% [1]

Core Viewpoint - The company is accelerating the registration and certification of its products in international markets while actively expanding its presence in overseas markets [1] Group 1: International Market Strategy - The company is focused on speeding up the registration and certification of its products for international markets [1] - The company is making efforts to establish a strong foothold in overseas markets [1] Group 2: Domestic Operations - The company has established medical testing laboratories in provinces such as Zhejiang, Jiangxi, Henan, Guangdong, and Shandong [1] - These laboratories provide testing services to medical institutions and engage in collaborative construction of medical testing laboratories [1]

Core Viewpoint - Capbio (SZ 300639) announced the convening of its sixth second board meeting on October 13, 2025, to discuss various proposals, including providing guarantees for its wholly-owned subsidiary and replacing some collateral under a syndicated loan [1] Financial Performance - For the first half of 2025, Capbio's revenue composition was as follows: molecular diagnostic products accounted for 67.65%, medical testing services for 29.07%, and medical service income for 3.27% [1] Market Position - As of the report, Capbio's market capitalization stood at 3.6 billion yuan [1]